SCHEMBL29373301

SCHEMBL29373301

CC(C)(O)c1ccc2ncc(-c3cccc(Br)n3)n2c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EIF2AK4 Q9P2K8 1/20 0.47
FLT3 P36888 9/20 0.45
GABRA1 P14867 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA3 P34903 1/20 0.44
MAP3K14 Q99558 1/20 0.41
IRAK4 Q9NWZ3 10/20 0.40
NRAS P01111 4/20 0.40
IRAK1 P51617 3/20 0.39
LCK P06239 1/20 0.39
RET P07949 1/20 0.39
PDGFRB P09619 1/20 0.39
CDK7 P50613 1/20 0.39
BLK P51451 1/20 0.39
CCNH P51946 1/20 0.39
KDR P35968 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24231440 1.00 EIF2AK4 (0.47) EIF2AK4FLT3GABRA1GABRG2GABRB3
SCHEMBL29370124 0.90 FLT3 (0.46) EIF2AK4FLT3GABRA1GABRG2GABRB3
SCHEMBL24231773 0.90 FLT3 (0.46) EIF2AK4FLT3GABRA1GABRG2GABRB3
SCHEMBL31068067 0.84 GABRA1 (0.48) EIF2AK4FLT3GABRA1GABRG2GABRB3
SCHEMBL24574150 0.84 GABRA1 (0.48) EIF2AK4FLT3GABRA1GABRG2GABRB3
SCHEMBL24231689 0.81 GABRA1 (0.49) FLT3GABRA1GABRG2GABRB3GABRA3
SCHEMBL29373972 0.81 GABRA1 (0.49) FLT3GABRA1GABRG2GABRB3GABRA3
SCHEMBL26358849 0.80 FLT3 (0.49) FLT3GABRA1GABRG2GABRB3GABRA3
SCHEMBL24573963 0.78 GABRA1 (0.50) EIF2AK4FLT3GABRA1GABRG2GABRB3
SCHEMBL30638516 0.78 GABRA1 (0.50) EIF2AK4FLT3GABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022026935-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2022-02-03 WO disclosed